Benzinga | Jun 1, 2021 08:04AM EDT

Cantor Fitzgerald Maintains Overweight on Biohaven Pharma Hldgs, Raises Price Target to $140

Cantor Fitzgerald analyst Charles Duncan maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Overweight and raises the price target from $125 to $140.